Evidence mapPaperPMID 39532948Full record

ArticleScientific reports2024

A predicted epithelial-to-mesenchymal transition-associated mRNA/miRNA axis contributes to the progression of diabetic liver disease.

Alina-Veronica Ghionescu, Andrei Sorop, Ekaterini Linioudaki, Cristin Coman, Lorand Savu, Marton Fogarasi, Daniela Lixandru, Simona Olimpia Dima

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Alina-Veronica Ghionescu *Center of Excellence in Translational Medicine, Fundeni Clinical Institute, Bucharest, Romania.
Andrei Sorop *Center of Excellence in Translational Medicine, Fundeni Clinical Institute, Bucharest, Romania.
Ekaterini LinioudakiCenter of Excellence in Translational Medicine, Fundeni Clinical Institute, Bucharest, Romania.
Cristin ComanCenter of Excellence in Translational Medicine, Fundeni Clinical Institute, Bucharest, Romania.
Lorand SavuCenter of Excellence in Translational Medicine, Fundeni Clinical Institute, Bucharest, Romania.
Marton FogarasiCenter of Excellence in Translational Medicine, Fundeni Clinical Institute, Bucharest, Romania.
Daniela LixandruCenter of Excellence in Translational Medicine, Fundeni Clinical Institute, Bucharest, Romania. daniela.lixandru@umfcd.ro.
Simona Olimpia DimaCenter of Excellence in Translational Medicine, Fundeni Clinical Institute, Bucharest, Romania.

Funding

CCCDI-UEFISCDI, project number PN-III-P2-2.1-PED-2021-3180, within PNCDI III 629PED/2022UMFCD 28571/02.10.2023
6 · The paper itself

Abstract

Despite public health measures, type 2 diabetes (T2D) is still a significant concern worldwide, given its associated complications, including hepatic alterations. The role of epithelial-to-mesenchymal transition (EMT) in liver fibrosis is well established. However, its effects on the progression of diabetic liver diseases are not well understood. Therefore, this study aims to investigate the mRNA/miRNA axes involved in this process. Bioinformatic analysis revealed new EMT-associated genes (CDH2, ITGB1, COL4A1, COL1A1, TNC, CCN2, and JUN), which showed higher expression in obese T2D and hepatocellular carcinoma (HCC) patients. In addition, six miRNAs (miR-21-5p, miR-26a-5p, miR-34a-5p, miR-106a-5p, miR-320a-3p and miR-424-5p) have been found as potential targets. Among them, miR-26a-5p and miR-424-5p were significantly downregulated in nonalcoholic steatohepatitis (NASH) and HCC (p < 0.05), being considered potential negative regulators of the EMT process. In our hepatic mesenchymal culture model, miR-26a-5p negatively regulated cadherin 2 (also known as N-cadherin, CDH2) and promoted the cadherin 1 (also known as E-cadherin, CDH1) expression. Our results reveal potential molecules involved in liver tumor development. Moreover, we observe that miR-26a-5p impairs EMT in the initial stages of diabetic liver disease by inhibiting CDH2 and could be a valuable target in this pathology.

Indexed as

Carcinoma, HepatocellularDiabetes Mellitus, Type 2Disease ProgressionEpithelial-Mesenchymal TransitionLiver NeoplasmsMicroRNAsNon-alcoholic Fatty Liver DiseaseRNA, MessengerComputational BiologyHumansMaleMicroRNAsRNA, MessengerDiabetesEMT and MET processesLiver diseasesMiR-26a-5pMRNA-miRNA signatureN-cadherin

Identifiers

PMID39532948
PMCPMC11557572

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.